SAGE Therapeutics (NASDAQ:SAGE) announced its earnings results on Thursday. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.98) by $0.23, Bloomberg Earnings reports. During the same period in the previous year, the business earned ($1.50) EPS.
SAGE Therapeutics (NASDAQ:SAGE) opened at $155.40 on Friday. SAGE Therapeutics has a 52 week low of $59.57 and a 52 week high of $195.97.
A number of brokerages have recently issued reports on SAGE. BidaskClub lowered SAGE Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, February 13th. BMO Capital Markets reaffirmed an “outperform” rating and set a $112.00 target price (up from $85.67) on shares of SAGE Therapeutics in a research report on Friday, November 17th. Needham & Company LLC lifted their target price on SAGE Therapeutics from $100.00 to $193.00 and gave the stock a “buy” rating in a research report on Thursday, December 7th. Raymond James Financial lifted their target price on SAGE Therapeutics to $109.00 and gave the stock a “buy” rating in a research report on Thursday, November 9th. Finally, JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a $198.00 target price on shares of SAGE Therapeutics in a research report on Friday, December 8th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and twelve have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $171.21.
In related news, insider Albert Robichaud sold 60,000 shares of SAGE Therapeutics stock in a transaction dated Thursday, December 14th. The stock was sold at an average price of $159.43, for a total value of $9,565,800.00. Following the completion of the transaction, the insider now directly owns 152,759 shares in the company, valued at $24,354,367.37. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Stephen Kanes sold 44,000 shares of SAGE Therapeutics stock in a transaction dated Wednesday, January 10th. The stock was sold at an average price of $177.18, for a total value of $7,795,920.00. Following the completion of the transaction, the insider now owns 46,348 shares of the company’s stock, valued at $8,211,938.64. The disclosure for this sale can be found here. Insiders sold 314,247 shares of company stock valued at $50,465,110 over the last quarter. Insiders own 6.10% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “SAGE Therapeutics (SAGE) Issues Quarterly Earnings Results” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/23/sage-therapeutics-sage-issues-quarterly-earnings-results.html.
SAGE Therapeutics Company Profile
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.